Angle PLC Result of General Meeting (0297V)
18 July 2018 - 7:34PM
UK Regulatory
TIDMAGL
RNS Number : 0297V
Angle PLC
18 July 2018
For immediate release 18 July 2018
ANGLE plc ("the Company")
Result of General Meeting and update re: EIS/VCT Advanced
Assurance
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that, further to the announcement
on 25 June 2018, the Resolutions put to Shareholders at the General
Meeting earlier today were duly passed.
Completion of the Fundraising is conditional on Admission of the
EIS/VCT Placing Shares becoming effective ("EIS/VCT Admission") and
Admission of the General Placing Shares and General Subscription
Shares becoming effective ("General Admission").
The issue of the EIS/VCT Placing Shares is conditional upon the
Company receiving advanced assurance from HMRC that an investment
in the Company will qualify for EIS and VCT tax reliefs (the
"Advanced Assurance") and on EIS/VCT Admission.
The issue of the General Placing Shares is conditional upon
General Admission and the EIS/VCT Admission.
The Company received Advanced Assurance from HMRC for the
purposes of EIS tax relief on 3 July 2018. Regarding VCT tax
relief, in the same correspondence, HMRC requested information on
the VCT investment in respect only of the names of investors, the
amounts being invested by these investors and confirmation of the
terms of investment. This information was provided to HMRC on 3
July 2018, the same day, and the Company is awaiting a response
from HMRC for the purposes of advance assurance for VCT tax relief
("VCT Advanced Assurance").
The qualification requirements for EIS and VCT tax relief are
the same and consequently the Company expects to receive VCT
Advanced Assurance from HMRC in the near term.
Therefore, EIS/VCT Admission is deferred until such time that
the VCT Advanced Assurance is received from HMRC. As the issue of
the General Placing Shares is conditional upon EIS/VCT Admission,
General Admission will also be deferred pending receipt of VCT
Advanced Assurance and is expected to occur the Business Day after
EIS/VCT Admission.
Further information regarding revised settlement and admission
dates will be announced via RNS in due course.
Capitalised terms not otherwise defined in this announcement
shall have the same meaning ascribed to such terms in the
announcement released on 25 June 2018 unless the context requires
otherwise.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Adrian Hargrave,
Simon Hicks, Max Bullen-Smith
Corporate Broking - Alice Lane, Nikita
Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample
types. A proprietary chemistry allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. These technologies can be combined to provide fully
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats. It is ideal for measuring gene
expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGLIFVADVITLIT
(END) Dow Jones Newswires
July 18, 2018 05:34 ET (09:34 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024